Kiadis Pharma Revenue and Competitors
Estimated Revenue & Valuation
- Kiadis Pharma's estimated annual revenue is currently $16.4M per year.
- Kiadis Pharma's estimated revenue per employee is $155,000
Employee Data
- Kiadis Pharma has 106 Employees.
- Kiadis Pharma grew their employee count by -28% last year.
Kiadis Pharma Competitors & Alternatives
| Competitor Name | Revenue | Number of Employees | Employee Growth | Total Funding | Valuation |
|---|---|---|---|---|---|
#1 | $11M | 71 | 0% | N/A | N/A |
#2 | $1.7M | 27 | 17% | N/A | N/A |
#3 | $60.3M | 389 | 11% | N/A | N/A |
#4 | $16.4M | 106 | -28% | N/A | N/A |
#5 | $29.6M | 153 | 14% | $45.5M | N/A |
#6 | $9.8M | 63 | 43% | N/A | N/A |
#7 | $4.9M | 77 | 26% | N/A | N/A |
#8 | $13M | 84 | -3% | $179.8M | N/A |
#9 | $18.8M | 121 | -15% | N/A | N/A |
#10 | $6M | 39 | -9% | N/A | N/A |
What Is Kiadis Pharma?
Kiadis Pharma is a clinical stage biopharmaceutical company focused on research, development and future commercialisation of cell-based immunotherapy products for the treatment of blood cancers and inherited blood disorders. Kiadis Pharma is committed to developing innovative and potentially life'saving therapies for patients with late-stage blood cancers and patients with inherited blood disorders, who are in need of a transplant, an area of significant unmet medical need.
keywords:N/A
N/A
Total Funding
106
Number of Employees
$16.4M
Revenue (est)
-28%
Employee Growth %
N/A
Valuation
N/A
Accelerator
Kiadis Pharma News
Kiadis Pharma; Cytovia Therapeutics; Nkarta, Inc; Fate Therapeutics; EMERcell; Glycostem; Phio Pharmaceuticals, Innate Pharma, Inc...
... Kiadis Pharma; OBI Pharma; Astellas Pharma Inc. and Medexus Pharma, Inc. Acute Lymphocytic/Lymphoblastic Leukemia (ALL) Therapeutics...
Bluebird Bio; Novartis; Kiadis Pharma; Acceleron Pharma. Alpha Thalassemia Market Breakdown by Type: Iron Chelating Drugs; Gene Therapy.
Amsterdam, The Netherlands - Kiadis Pharma N.V. ('Kiadis Pharma' or the 'Company') (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, announces that its Annual General Meeting of shareholders ('AGM') will be held at 15:00 CEST on 28 June 2021. Pursuant to tempor ...
Amsterdam, The Netherlands, 13 May 2021 – Kiadis Pharma N.V. (“Kiadis Pharma” or the “Company”) (Euronext Amsterdam and Brussels: KDS), a clinical-stage biopharmaceutical company, today announces that its Annual General Meeting of shareholders ("AGM”) will be held at 15:00 CEST on 28 June 2021. ...
Other Companies in Amsterdam
| Company Name | Revenue | Number of Employees | Employee Growth | Total Funding |
|---|---|---|---|---|
#1 | $13.8M | 106 | -10% | N/A |
#2 | $26.5M | 106 | 14% | N/A |
#3 | $15.4M | 106 | -14% | N/A |
#4 | $22.3M | 106 | 2% | N/A |
#5 | $21.7M | 106 | 38% | N/A |
